About BiondVax (NASDAQ:BVXV)
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529
Debt
Debt-to-Equity RatioN/A
Current Ratio10.97
Quick Ratio10.97
Price-To-Earnings
Trailing P/E Ratio-3.48
Forward P/E Ratio-172.50
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book2.78
Profitability
EPS (Most Recent Fiscal Year)($1.98)
Net Income$-9,960,000.00
Net MarginsN/A
Return on Equity-78.39%
Return on Assets-55.34%
Miscellaneous
Employees14
Outstanding Shares6,530,000
BiondVax (NASDAQ:BVXV) Frequently Asked Questions
What is BiondVax's stock symbol?
BiondVax trades on the NASDAQ under the ticker symbol "BVXV."
How were BiondVax's earnings last quarter?
BiondVax (NASDAQ:BVXV) issued its quarterly earnings data on Monday, April, 30th. The company reported ($0.59) EPS for the quarter. View BiondVax's Earnings History.
When is BiondVax's next earnings date?
Who are some of BiondVax's key competitors?
Some companies that are related to BiondVax include Compugen (CGEN), Pluristem Therapeutics (PSTI), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Aptose Biosciences (APTO), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), Aevi Genomic Medicine (GNMX), Curis (CRIS), Brainstorm Cell Therapeutics (BCLI), Genocea Biosciences (GNCA), Champions Oncology (CSBR), CytRx (CYTR), TRACON Pharmaceuticals (TCON) and Vical (VICL).
Who are BiondVax's key executives?
BiondVax's management team includes the folowing people:
- Dr. Ron Babecoff DVM, Founder, Chief Exec. Officer, Pres & Director (Age 56)
- Mr. Uri Ben-Or, Chief Financial Officer (Age 48)
- Dr. Tamar Ben Yedidia Ph.D., Chief Scientific Officer (Age 54)
- Dr. Shimon Hassin Ph.D., Chief Operating Officer
- Mr. Joshua E. Phillipson, Bus. Devel. Mang.
When did BiondVax IPO?
(BVXV) raised $10 million in an initial public offering on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.
Has BiondVax been receiving favorable news coverage?
News headlines about BVXV stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BiondVax earned a media sentiment score of 0.06 on Accern's scale. They also gave media stories about the company an impact score of 47.11 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of BiondVax?
Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BiondVax's stock price today?
One share of BVXV stock can currently be purchased for approximately $6.90.
How big of a company is BiondVax?
BiondVax has a market capitalization of $45.09 million. The company earns $-9,960,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. BiondVax employs 14 workers across the globe.
How can I contact BiondVax?
BiondVax's mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]
MarketBeat Community Rating for BiondVax (BVXV)
MarketBeat's community ratings are surveys of what our community members think about BiondVax and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days.
BiondVax (NASDAQ:BVXV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
